HEALTHSTORY 843· JUNE 20, 2026

Daraxonrasib Doubles Average Survival in Pancreatic Cancer, UCLA-Led Trial Shows

A UCLA-co-led international study presented May 31 at the American Society of Clinical Oncology annual meeting in Chicago reported that pancreatic cancer patients treated with daraxonrasib survived an average of 13.2 months — nearly double…

NDNewsDialy Desk2 MIN READ

SOURCE

statnews.com

← PREVIOUS STORY 842Nuclear Bros: Silicon Valley's Young Founders Race to Restart American Atomic Power NEXT STORY 844 →U.S. Confirms Second Strike on Iran Targeting Air Defenses as Oil Prices Surge

Keep reading

More from the desk.

20HEALTH

Federal vaccine messaging is making new parents' decisions harder, says the AAP president

Fearmongering (spreading exaggerated alarm to shift behavior, rather than to inform a decision) is what some federal leaders are doing on childhood vaccines, the president of the American Academy of Pediatrics now argues. The AAP is the…

health2 MIN

24HEALTH

Federal investigators are examining Epic Systems over potential antitrust violations

Federal regulators are looking at whether the nation's largest electronic health records company violated competition law. Antitrust law, which bars dominant companies from using their market position to lock out rivals, is the framework…

health2 MIN

38HEALTH

FDA clears first CELMoD drug for blood cancer as a $6.7 billion shareholder lawsuit returns to court

Multiple myeloma, a blood cancer, now has a new oral treatment approved by U.S. regulators. The Food and Drug Administration cleared Zenbexus, made by Bristol Myers Squibb, as the first drug in a new class called CELMoDs and the first drug…

health2 MIN

Tomorrow · 06:00

Start tomorrow already ahead.

Five stories, a two-minute read, zero noise — the world before your first coffee.

Get the 6AM brief Back to the desk